In this study, we tried to determine the KRAS mutation subtype and the extent of the mutation burden in cell-free DNA (cfDNA) as well as in the tumor tissues of patients with pancreatic cancer using ddPCR. The gene discussed is KRAS; the disease is neoplasm.